Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-Hodgkin’s lymphoma (all ages)
This activity is now closed…
Unfortunately, this activity is now closed and no more online responses will be accepted.
Unfortunately, this activity is now closed and no more online responses will be accepted.